HTA dossier preparation
Health-economic evidence packages — systematic clinical-evidence reviews, cost-effectiveness and budget-impact modeling, patient-perspective data — that a biopharma manufacturer must assemble to win pricing and reimbursement approval from a national HTA body (NICE, G-BA, CADTH), prepared by specialty consultancies against strict statutory deadlines (56 days for a NICE Single Technology Appraisal), increasingly using AI to compress a traditionally months-long process.
1 · What it gives
HTA dossier preparation assembles the health-economic evidence package a biopharma manufacturer must submit to a national health technology assessment body — NICE in the UK, G-BA in Germany, CADTH in Canada — to win a pricing and reimbursement decision after a drug or device already has regulatory marketing authorization. A NICE Single Technology Appraisal gives manufacturers a hard 56-calendar-day deadline to submit a full evidence dossier once scoping is complete, and Germany’s AMNOG dossier for the G-BA carries similarly compressed timelines. One specialty consultancy has prepared over 370 HTA submission dossiers, more than 135 to NICE alone; another has built an in-house AI tool that compressed a full German AMNOG dossier’s production time to three months. This is a distinct advisory service from the CMC regulatory filing and market-access manufacturing services already covered on this site — HTA dossier work happens after regulatory approval, building the separate economic case a payer needs to agree to reimburse the product, not the safety/efficacy case a regulator needs to approve it.
Key directions of HTA dossier preparation:
- Systematic evidence review (Systematic Evidence Review): structured literature reviews and network meta-analyses building the clinical comparator evidence base an HTA submission requires.
- Cost-effectiveness and budget-impact modeling (Cost-Effectiveness Modeling): health-economic models calculating a therapy’s cost-per-outcome and budget impact against national HTA methodology standards.
- AI-assisted dossier generation (AI-Assisted Dossier Generation): AI tools that convert structured clinical trial data into the narrative sections an HTA dossier requires, compressing production timelines.
- Payer and HTA stakeholder engagement (Stakeholder Engagement): structured advisory support for the negotiation and scientific-advice stages of an HTA submission process.
Sectoral value chain#
[regulatory marketing authorization] ──> [evidence synthesis] ──> [economic modeling] ──> [dossier assembly]
│
(HTA body statutory deadline)
│
▼
[pricing/reimbursement decision] <─── [HTA body submission] <──┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Scoping | defining the HTA submission’s comparator and population scope | In: regulatory approval, target HTA body requirements. Out: submission scope document. |
| Evidence synthesis | systematic review and network meta-analysis of clinical data | In: clinical trial data, published literature. Out: synthesized evidence base. |
| Economic modeling | cost-effectiveness and budget-impact model construction | In: evidence base, cost data. Out: health-economic model outputs. |
| Dossier assembly | compiling the full submission document per HTA body format | In: evidence, model outputs. Out: complete HTA dossier. |
| Submission & review | formal submission and response to HTA body evidence requests | In: complete dossier. Out: HTA body evaluation, clarification responses. |
| Decision & negotiation | pricing/reimbursement decision and any negotiated agreement | In: HTA evaluation. Out: reimbursement decision, price agreement. |
Cross-cutting technologies:
- AI-assisted dossier generation (AI-Assisted Dossier Generation): software converting structured clinical data into HTA-required narrative documentation.
- Cost-effectiveness modeling (Health-Economic Modeling): statistical and economic models calculating cost-per-outcome against HTA methodology standards.
- AMNOG/NICE submission workflow (Statutory-Deadline Submission Workflow): structured project-management processes built around each HTA body’s specific statutory submission deadlines.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 6 steps
- 1ScopingThe consultancy and manufacturer agree the submission’s target population, comparator therapies and outcome measures based on the HTA body’s published scoping document.
- 2Evidence synthesisSynthesis & conversionA systematic literature review and network meta-analysis assembles the clinical evidence base, including indirect comparisons where no direct head-to-head trial against every relevant comparator exists.Who can do this step matched automatically163,050 tonnes“Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”✓ ISO 9001 30,000 tons per industrial scale“Enzymes for Protein Hydrolysis”“2026-06-28 [BIOCATALYST LEADERSHIP: How Enzymes are Propelling India's Pharma Bio Spectrum - business - Read this story on Magzter.com — A brief mention of Aum Enzymes or Infinita …”
- 3Economic modelingA cost-effectiveness and budget-impact model is built to the specific methodology the target HTA body requires, calculating cost-per-outcome and national budget impact.
- 4Dossier assemblyRegulatory & certificationEvidence synthesis and modeling outputs are compiled into the complete dossier document, in the exact format and section structure the HTA body mandates — increasingly assisted by AI tools that draft narrative sections from structured data.Registration in Russia / EAEU: Regulation
- 5SubmissionThe complete dossier is formally submitted within the HTA body’s statutory deadline — 56 calendar days for a NICE STA following scoping — and the consultancy manages responses to any evidence clarification requests.
- 6Decision and negotiationThe HTA body issues its pricing/reimbursement evaluation, with the consultancy supporting the manufacturer through any negotiation or appeal stage before a final reimbursement decision and price agreement.
4 · Who delivers
Matched suppliers (matched automatically)
| Biological Preparations | United Kingdom | Producer | active |
| AGRIBIO+ | Cameroon | Producer | active |
| Fresenius | Germany | Producer | active |
| National Animal Genetic Resources Centre & Data Bank (NAGRC&DB) | Uganda | Research / RTO | active |
In the services and supply catalogue 2 · paid service
Consulting & market access · Regulatory & certification
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Costello Medical | 🇬🇧 UK | Full HTA evidence packages (strategy through dossier writing) | 370+ HTA dossiers delivered, 135+ to NICE; B Corp certified; King’s Award for Enterprise 2025 | Commercial |
| Kintiga | 🇬🇧 UK | EPRI AI-assisted AMNOG/NICE/JCA dossier tool | AI-compressed AMNOG dossier production to 3 months; ~90 employees, 2 continents | Commercial |
| Lumanity | 🇺🇸 USA | HEOR and market-access advisory | Formed 2020 via Cello Health/BresMed/Guidemark Health merger; 1,200+ employees | Commercial |
| VantEdge Access | 🇺🇸 USA | AI-enabled HTA intelligence platform | US/Canada/EU-5 coverage; combines AI tooling with senior HEOR consulting | Commercial |
5 · Rules & route to market
United States
The US HTA landscape is shaped by a non-mandated but increasingly influential nonprofit assessor, with specialty consultancies built specifically around navigating its evidence expectations alongside private payer requirements.
ICER’s non-mandatory but influential role, AI-native and established consultancy models, private-payer evidence requirements#
- Lumanity (Bethesda, founded 2020): formed through the merger of several established health-economics and market-access firms including Cello Health and BresMed, with 1,200+ employees across the US, UK, Europe and India providing health-economics-and-outcomes-research services.
- VantEdge Access (Illinois, hubs in Chicago/Oak Brook and Paris): combines AI-enabled HTA intelligence with consulting expertise across the US, Canada and EU-5 markets, supporting biopharma teams through development, launch and lifecycle market-access strategy.
- ICER’s non-mandatory influence: unlike NICE or other statutory HTA bodies, ICER’s cost-effectiveness assessments are not mandated in the US, but its value-based price estimates increasingly shape payer negotiations and coverage decisions.
European Union
Europe hosts the field’s most established specialty consultancies, built around the UK’s NICE and Germany’s AMNOG processes, both running on strict statutory deadlines.
NICE 56-day statutory deadline, AMNOG AI-compressed dossier production, B Corp-certified global consultancy model#
- Costello Medical (Cambridge, UK): a B Corp-certified consultancy with offices spanning Europe, Asia-Pacific and North America, having developed over 370 HTA submission dossiers with 135+ submitted to NICE alone, and winner of the King’s Award for Enterprise in International Trade (2025).
- Kintiga (UK, ~90 employees): a pan-European market-access consultancy whose in-house AI tool (EPRI) compressed a full German AMNOG HTA dossier’s production to three months, alongside direct AMNOG negotiation support.
- NICE’s 56-day statutory deadline: manufacturers face a hard 56-calendar-day deadline to submit a full evidence dossier for a NICE Single Technology Appraisal once scoping concludes, the timeline pressure driving demand for specialty dossier-preparation services.
China
No confirmed China-domiciled HTA-specialist consultancy was found operating independently; international consultancies with China offices serve manufacturers navigating the National Reimbursement Drug List process instead.
NRDL as the reimbursement gateway, international-firm China offices, no confirmed domestic specialist#
- NRDL as the reimbursement gateway: inclusion on China’s National Reimbursement Drug List, administered by the National Healthcare Security Administration, determines whether a product is reimbursed nationally and is often the only path to prescription within public hospitals.
- NHDRC evaluation role: China’s National Health Development Research Center provides technical HTA consultancy to health policy-makers, with a panel of health-economic experts scoring each eligible drug — a government research-institution role rather than a private-vendor service.
- International firms’ China presence: established international HTA consultancies maintain Shanghai offices to serve manufacturers navigating NRDL submissions, but no independently confirmed China-domiciled specialist firm was found — left qualitative pending a real candidate.
6 · Money: tenders & grants
| Grant | Additional activities for the European Partnership of Agriculture of Data European Commission · EU | Nov 26, 2026 3 days |
| Grant | Boosting Innovative GEOINT - Science & Technology Broad Agency Announcement (BIG-ST BAA) National Geospatial-Intelligence Agency · United States | Dec 14, 2026 21 days |
| Grant | NSF Scholarships in Science, Technology, Engineering, and Mathematics Program U.S. National Science Foundation · United States | Mar 2, 2027 99 days |
| Grant | Open topic: Using the Circular Cities and Regions Initiative to strengthen urban manufacturing in support of … European Commission · EU | Apr 8, 2027 136 days |
| Grant | Powering Affordable Reliable Technology (PART) Energy Program Rural Utilities Service · United States | rolling |
7 · Tech stack & innovations
The category’s technical work spans health-economic methodology and, increasingly, AI tooling that compresses the traditionally document-heavy dossier-writing process.
- Cost-effectiveness modeling infrastructure (Health-Economic Model
Construction):
- Modelers build cost-effectiveness and budget-impact models specific to each HTA body’s required methodology — NICE’s reference-case requirements differ from G-BA’s AMNOG framework, requiring jurisdiction-specific model construction rather than a single reusable template.
- Network meta-analysis techniques let a dossier compare a therapy against multiple relevant comparators even when no direct head-to-head trial exists.
- AI-assisted dossier drafting (Structured-to-Narrative AI
Conversion):
- AI tools convert structured clinical trial data directly into the narrative sections an HTA dossier’s required format demands, compressing a process that traditionally took many months of manual medical writing.
- This is a live technical differentiator: one firm’s AI-assisted workflow completed a full AMNOG dossier in three months, a significantly compressed timeline versus traditional manual preparation.
- Statutory-deadline project management (Multi-Jurisdiction Submission
Workflow):
- Firms operating across multiple HTA bodies manage genuinely different statutory deadlines and evidence-format requirements in parallel — a NICE STA’s 56-day window differs from AMNOG’s own compressed timeline — requiring dedicated project infrastructure rather than a single generic consulting workflow.
Sources 4 · 0 independent · 4 producer sites
Producers' own sites 4
- Costello medical producer checked 2026-08-10 · link not kept
- Kintiga producer checked 2026-08-10 · link not kept
- Lumanity producer checked 2026-08-10 · link not kept
- Vantedge access producer checked 2026-08-10 · link not kept